A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix

R. E. Coleman; J. M. Clarke; M. L. Slevin; J. Sweetenham; C. J. Williams; P. Blake; F. Calman; E. Wiltshaw; P. G. Harper

doi:10.1007/BF00689276

A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix

R. E. Coleman, J. M. Clarke, M. L. Slevin, J. Sweetenham, C. J. Williams, P. Blake, F. Calman, E. Wiltshaw, P. G. Harper

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

A total of 44 women received a combination of ifosfamide (1.5 g/m² daily x5) and cisplatin (50 mg/m² on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (38%) evaluable patients responded, with the median duration of response being 7 months. Bone marrow and gastrointestinal toxicity were frequently severe. There were 3 septic death. Although cisplatin plus ifosfamide is an active combination against this disease, these results suggest that it is no more so than either drug used alone.

Original language	English (US)
Pages (from-to)	52-54
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	27
Issue number	1
DOIs	https://doi.org/10.1007/BF00689276
State	Published - Jan 1990
Externally published	Yes

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

Access to Document

10.1007/BF00689276

Cite this

@article{a709002cdd6f4afab8c5426a0806d7d7,

title = "A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix",

abstract = "A total of 44 women received a combination of ifosfamide (1.5 g/m2 daily x5) and cisplatin (50 mg/m2 on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (38%) evaluable patients responded, with the median duration of response being 7 months. Bone marrow and gastrointestinal toxicity were frequently severe. There were 3 septic death. Although cisplatin plus ifosfamide is an active combination against this disease, these results suggest that it is no more so than either drug used alone.",

author = "Coleman, {R. E.} and Clarke, {J. M.} and Slevin, {M. L.} and J. Sweetenham and Williams, {C. J.} and P. Blake and F. Calman and E. Wiltshaw and Harper, {P. G.}",

year = "1990",

month = jan,

doi = "10.1007/BF00689276",

language = "English (US)",

volume = "27",

pages = "52--54",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix

AU - Coleman, R. E.

AU - Clarke, J. M.

AU - Slevin, M. L.

AU - Sweetenham, J.

AU - Williams, C. J.

AU - Blake, P.

AU - Calman, F.

AU - Wiltshaw, E.

AU - Harper, P. G.

PY - 1990/1

Y1 - 1990/1

N2 - A total of 44 women received a combination of ifosfamide (1.5 g/m2 daily x5) and cisplatin (50 mg/m2 on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (38%) evaluable patients responded, with the median duration of response being 7 months. Bone marrow and gastrointestinal toxicity were frequently severe. There were 3 septic death. Although cisplatin plus ifosfamide is an active combination against this disease, these results suggest that it is no more so than either drug used alone.

AB - A total of 44 women received a combination of ifosfamide (1.5 g/m2 daily x5) and cisplatin (50 mg/m2 on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (38%) evaluable patients responded, with the median duration of response being 7 months. Bone marrow and gastrointestinal toxicity were frequently severe. There were 3 septic death. Although cisplatin plus ifosfamide is an active combination against this disease, these results suggest that it is no more so than either drug used alone.

UR - http://www.scopus.com/inward/record.url?scp=0025614853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025614853&partnerID=8YFLogxK

U2 - 10.1007/BF00689276

DO - 10.1007/BF00689276

M3 - Article

C2 - 2245492

AN - SCOPUS:0025614853

SN - 0344-5704

VL - 27

SP - 52

EP - 54

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 1

ER -

A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this